| | | |
ACR ≥ 20 responses at
|
|---|
|
Study/Trial
|
Mean disease duration
|
Median MTX dose (mg/week)
|
12 months
|
24 months
|
|---|
|
Haagsma, et al. [74]
|
3 months
|
10
|
71%
|
NR
|
|
Möttönen, et al. [57]
|
8 months
|
10
|
78%
|
84%
|
|
ERA [12, 75]
|
11 months
|
18a
|
65%
|
59%
|
|
MN 302 [15]
|
3.8 years
|
10
|
65%b
|
72%
|
|
US 301 [5]
|
6.5 years
|
15a
|
46%b
|
67%
|
|
ASPIRE [10]
|
7 months
|
19a
|
54%b
|
NR
|
|
TEMPO [13]
|
6.6 years
|
17a
|
75%
|
71%
|
|
PREMIER [11]
|
8 to 9 months
|
16a
|
63%b
|
56%
|
- Therapeutic responses to methotrexate (MTX) are not consistent across trials and cannot be explained solely by differences in duration of disease or median MTX dose. aWith regular folate supplementation. bDesignated 12 month outcomes were analyzed with an intention to treat (ITT) analysis with non-responder imputation (NRI) for study non-completers. All other 12 month outcomes were analyzed by ITT with last observation carried forward (LOCF) for non-completers. ACR, American College of Rheumatology; ASPIRE, Active Controlled Study of Patients Receiving Infliximab for Treatment of Rheumatoid Arthritis of Early Onset; ERA, Early Rheumatoid Arthritis; NR, not recorded; TEMPO, Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes.
